The ratio of tumor-infiltrating PD-1+CD8+ T-cells relative to Tregs was a superior predictor of therapeutic responses than all other predictors, including PD-L1 expression and tumor mutational burden. The gene discussed is PDCD1; the disease is neoplasm.